St Jude

It’s all getting a bit heated as Medtronic and St. Jude lock horns again, this time over the Hauser publication in Heart Rhythm journal.

According to St Jude, Dr Robert Hauser’s paper, accepted for publication in the Heart Rhythm Journal is biased and inaccurate, comparing apples with pears and peddling conclusions it’s own analysis cannot reproduce from the data set. Watch this space.

St Jude medical is taking the initiative over more of its leads in which so-called externalisation can result in problems, by issuing a physician advisory letter.

Thoughtful and insightful blog post from today on theheart.org

St Jude has recalled and suspended sales of its Brio Deep Brain Stimulation system until it resolves the issue of body fluid ingress, which it believes is causing a lack of therapeutic effect.

St Jude is quite keen to own the moral high ground as it issues a retort to a Heart Rhythm Journal publication, which it believes relies on data which is “not entirely accurate.”

St Jude’s ICD Lead Data will now be collected and analysed by 3rd party specialist researchers, the Population Health Research Institute.

Everolimus stents appear top dog in long term stent thrombosis meta-analysis.

St Jude agrees to a fixed forward royalty payments and to ongoing exclusive use of Kensey Nash’s Collagen in its AngioSeal device following mediated settlement.

St Jude’s Riata problems have been covered by Minneapolis’ Star Tribune with a report on the recent summit and the tale of a re-do patient.

Initial results of ReCor’s REDUCE First-In-Man clinical study presented at “TRenD 2012” transcatheter renal denervation scientific meeting as company gains CE mark for its PARADISE™ system.

St Jude is pretty bullish about FFR measurement as a diagnostic tool in assessing coronary artery disease, based on favourable outcome from previous studies. It’s now supporting a country-specific evaluation of the cost effectiveness of an FFR-guided intervention strategy for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.

St Jude Medical’s fighting talk in response to NEJM editorial suggesting its surveillance procedures are lacking and that Durata may suffer the same fate as its older brothers.

FDA approves cardiac ablation products from St Jude.

Details of UK MHRA’s alert relating to St Jude’s Riata defibrillator leads.

A sizeable group of clinicians and St Jude representatives have met to discuss the issue of “externalised” Riata implantable defibrillator leads.